The Cut-off Point of Interleukin-6 Level in Acute Coronary Syndrome
|
|
- Stanley Washington
- 5 years ago
- Views:
Transcription
1 ORIGINAL ARTICLE The Cut-off Point of Interleukin-6 Level in Acute Coronary Syndrome Idrus Alwi*, T Santoso*, Slamet Suyono**, Bambang Sutrisna***, Siti Boedina Kresno**** ABSTRACT Aim: this study aimed to observe whether the interleukin-6 level in acute coronary syndrome (ACS) patients were higher than those in coronary heart disease (CHD) patients. In addition, we would like to observe the cut off point of interleukin-6 level in ACS. Methods: this cross sectional study were conducted at Dr. Cipto Mangunkusumo General Hospital (RSUPN-CM), Persahabatan Hospital, MMC Hospital and Medistra Hospital, Jakarta. The study started from 1 May 2005 to 5 May Results: in this observational study, as many as 62 CHD patients were collected and 84 ACS that met the study criteria. Demographic analysis showed that there was no difference in ages among the two groups (ACS and CHD). The risk factors of dyslipidemia, hypertension and lipid profile in the two groups did not differ significantly. Waist circumference and IMT, systolic and diastolic blood pressures in the two groups did not also differ signi cantly. Smoking was more prevalent in the groups of ACS than in the groups of CHD. In this study the IL-6 level in ACS (mean 40.85pg/mL, SD 41.71, CI 95% was higher than that in CHD (mean 4.58 pg/ml, SD 9.61, CI 95% ). To identify the IL-6 level as the predictor for the occurrence of ACS, sensitivity and speci city were calculated at various cut-off points of IL-6 level. At cut-off point of IL-6 ³ 4.43 pg/ml the highest sensitivity (89.95%) and highest speci city (77.42%) were found with ROC of Conclusion: it could be concluded that the IL-6 level in ACS were higher that those in CHD. The IL-6 level ³ 4,43 pg/ml could differentiate the acute condition (ACS) and stable condition (non-acs) with sensitivity of 89.95% and speci city of 77.42%, and ROC of Key words: interleukin-6, acute coronary syndrome. * Division of Cardiology, ** Division of Metabolic-Endocrinology and Diabetes, Department of Internal Medicine Faculty of Medicine University of Indonesia-Dr. Cipto Mangunkusumo General Hospital, Jakarta, *** Department of Epidemiology, Faculty of Public Health, University of Indonesia, Jakarta,**** Department of Clinical Pathology, Faculty of Medicine University of Indonesia/Dr. Cipto Mangunkusumo General Hospital, Jakarta INTRODUCTION Atherosclerosis and its associated manifestations including acute coronary syndrome (ACS), has been proven as a chronic inflammatory disease. 1-4 Acute coronary syndrome is associated with release of proinflammatory mediators from macrophage and T-lymphocytes, such as tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1) and interleukin-6 (IL-6). These cytokines will stimulate production of acute phase reactants, C- reactive protein (CRP), in the liver. 1 Besides CRP, other in ammatory marker commonly being studied is proin ammatory cytokines. 5-7 Studies revealed that the level of proin ammatory cytokines such as IL-1β and IL-6 increase in stable 8 and unstable angina pectoris, 9 and also in acute myocardial infarction (AMI). 10 Serum interleukin-6 level is a risk factor for AMI in healthy men. 11 Studies on serum interleukin-6 level in ACS, especially to establish an interleukin-6 cutoff level in ACS patients in Indonesia, have never been reported. METHODS This is a comparative observational cross-sectional study. Patients in ACS group is compared with patients in CHD group. Measurement of serum IL-6 level could well illustrate proin ammatory response, both acute and chronic. Time and Location of Study The study was performed at the intensive coronary care unit (ICCU) in Cipto Mangunkusumo National General Hospital (CMNGH)/Faculty of Medicine University of Indonesia (FMUI), Persahabatan Hospital, Metropolitan Medical Center (MMC) Hospital, Medistra Hospital, Cardiology Outpatient Clinic Department of Internal Medicine FMUI- CMNGH, and Integrated Heart Service Outpatient Clinic CMNGH. The study was performed from May 2005 to May
2 Vol 39 Number 4 October - December 2007 The Cut-off Point of Interleukin-6 in Acute Coronary Syndrome Patient Population Subjects being studied were ACS patients being hospitalized at the ICCU of CMNGH, Persahabatan Hospital, MMC Hospital, and Medistra Hospital. Patients were matched for age and sex. Control group for CHD was taken from patients visiting Cardiology Outpatient Clinic Department of Internal Medicine FMUI-CMNGH and Integrated Heart Service Outpatient Clinic CMNGH. Informed consent will be obtained from the patient after the patient is given explanations from the researcher / research assistant. Permission to perform the study was obtained from FMUI Research Ethics Committee. Estimation of Sample Size In this part the in ammatory response values in ACS was compared with that in CHD. Estimation of sample size used the t-test formula for 2 independent groups: n = 2 (SD 2 (zα + zβ) 2 ) / d 2 ; with n: number of subjects in each group, SD: standard deviation of dependent variable, Zα: normal standard deviation for α; if α=0.05, two-way test, then Zα=1.96, Zβ: normal standard deviation for β; if β=0.20, then Zβ= 0.84, d: mean difference of ACS patients compared to control group In ammatory Response From previous studies we found some in ammatory response parameters as follows: mean serum IL-6 value in a study by Smith et al. 12 : in unstable angina pectoris (UAP) 20.9 pg/ml (SD=18.7) and in stable angina pectoris (SAP) 11.4 pg/ml (SD=4.2). Inclusion and Exclusion Criteria The inclusion criteria were ACS patients undergoing hospitalization in ICCU CMNGH, Persahabatan Hospital, MMC Hospital, and Medistra Hospital ful lling ACS criteria with onset <72 hours, CHD patients visiting CMNGH Cardiology Outpatient Clinic and Integrated Heart Service Outpatient Clinic, who are willing to participate in the study and sign the informed consent. The exclusion criteria were currently having acute or chronic infection, having diseases associated with in ammatory response such as autoimmune disease, connective tissue disease and neoplasm, trauma or surgery within the last 1 month, currently receiving corticosteroid, NSAID or immunosuppressive therapy, CHD patients receiving statin therapy, ACS patients receiving statin after blood sample for in ammatory response (before intervention) was collected (for observational study), receiving thiazolidindione therapy, currently suffering from chronic renal disease and chronic liver disease. Recorded Parameters/Variables Anamnesis included age, sex, education level, ethnicity, history of previous chest pain and myocardial infarction, smoking habit, previous history of medication, history of hypertension, history of diabetes mellitus, history of dyslipidemia, family history of heart disease. Physical examination: blood pressure, heart physical examination, body height, body weight, waist circumference. Clinical laboratory examination included peripheral blood count: hemoglobin, hematocrit, leukocyte, thrombocyte; CK, CKMB, troponin T, fasting and postprandial serum glucose concentration, glyco Hb, total cholesterol level, direct LDL cholesterol level, HDL cholesterol level and triglyceride, ureum, creatinine, SGOT, SGPT. In ammatory response: serum IL-6 level. Acute coronary syndrome (ACS) 13,14 : a spectrum of heart emergency consists of: acute myocardial infarction with ST elevation (ST-elevated myocardial infarction/stemi), acute myocardial infarction without ST elevation (non ST-elevated myocardial infarction/ NSTEMI), unstable angina pectoris (UAP). Unstable angina pectoris 15 was de ned according to Braunwald s classi cation (ful lling one of the following criteria): 1. Angina found during rest and lasts for a long time, usually lasts more than 20 minutes. 2. New onset angina classi ed as IIIrd class or above in the Canadian Cardiovascular Society (CCS) classi cation. 3. Acceleration of new angina with signs of increased severity of angina at least 1 CCS to at least IIIrd class of CCS. Canadian Classi cation of Angina: 16 I. Angina only occurs with severe activity. II. Moderate activity, such as walking more than 1 oor, causes angina. III. Mild activity, such as walking less than 1 oor, causes angina. IV. All activities, even resting, causes angina. Criteria used to diagnose acute myocardial infarction (AMI) 17 were characteristic elevation and gradual decline (troponin) or earlier elevation and decline of biochemical markers of myocardial necrosis with at least one of the following symptoms: a. Ischemic symptoms, b. Occurrence of pathologic Q wave in the ECG. c. Changes in ECG waves indicating ischemia (elevation or depression of ST segment). d. Coronary artery intervention (e.g. coronary angioplasty). Coronary heart disease (CHD) was de ned as a coronary heart disease patients not currently having acute coronary syndrome based on anamnesis and ECG, and proved having a history of CHD based on previous coronary angiography examination or having a history of acute myocardial infarction/acs at least 6 months before the examination. 175
3 Idrus Alwi, et al Acta Med Indones-Indones J Intern Med Age was measured as the age on the day of examination according to the Citizen Identification Card, if over 6 months should be rounded up and if below 6 months should be rounded down. Body weight: in kilogram (kg) measured using SECA digital 770 weighing scale. Body height: in centimeter (cm) measured using Microtois CMS equipment. Body mass index (BMI): in kg/m 2 calculated using the following formula: body weight (kg) / body height (m) 2. Waist circumference is measured using SECA 200 measuring tape. In ammatory Response Serum interleukin-6 level: in pg/ml, using enzyme immunoassay method. Reagent being used is Quantikine R from R&D System, Inc. 614 McKinley Place NE, Minneapolis, MN 55413, USA. Normal value ranges between pg/ml. Intra assay variability is % and inter assay variability is %. Laboratory Assays For routine blood count and blood chemistry analysis, fasting peripheral venous blood sample (10-12 hours) was collected, then the second blood sample was taken for 2 hour postprandial blood glucose level, using standard method, and sent to the Clinical Laboratory. Sample for serum IL-6 level measurement was taken from venous blood using standard method and sent to the Clinical Laboratory. ACS patients being hospitalized at the ICCU of CMNGH, Persahabatan Hospital, MMC Hospital, and Medistra Hospital were selected using consecutive sampling between May 2005 and May 2006, while CHD patients were selected using consecutive sampling at the CMNGH Cardiology Outpatient Clinic and Integrated Heart Service Outpatient Clinic within the same period of time. CHD patients were only taken from CMNGH Outpatient Clinic because the number of cases was enough so that the samples did not have to be collected from other hospitals. Statistical Analysis All data obtained were continuous data. The data were coded, tabulated using STATA, and calculated statistically. Normally distributed variables went through parametric tests, and variables with abnormal distribution went through transformation, so as to be compliant with parametric test. All calculations used p < 0.05 as the level of signi cance, calculated using STATA statistical program. In order to compare in ammatory response between ACS and CHD patients, serum IL-6 level variable, continuous, abnormal distribution, logarithmic transformation was performed in order to obtain a normal data distribution, parametric statistical test was used; the t 2 test for different samples. RESULTS Serum IL-6 Level in ACS Group and CHD Group In this study, the serum IL-6 level in ACS (mean pg/ml, SD 51.71, CI 95 % ) is higher compared to CHD (mean 4.58 pg/ml, SD 9.61, CI 95 % ). Table 1 demonstrates serum IL-6 level at cut-off point > 4.43 pg/ml shows highest sensitivity and speci city. Cutoff Point of Serum IL-6 Level in ACS Group Compared to CHD Group In order to investigate serum IL-6 level as a predictor of ACS, sensitivity and speci city of serum IL-6 level were calculated for the ACS group in various levels of serum IL-6. In serum IL-6 cutoff point > 4.43 pg/ml, we obtained the highest sensitivity and speci city. The sensitivity and speci city of serum IL-6 level 4.43 pg/ml above is illustrated as the receiver operating characteristic (ROC) curve as seen in Figure 1 with ROC DISCUSSION Interleukin-6 is known as a proinflammatory cytokine that could stimulate T-lymphocyte and B-lymphocyte, and stimulate acute phase proteins such as hscrp in the liver. 18 The IL-6 is induced by various stimulations, such as tumor necrosis factor, IL-1, interferon-γ, virus, and bacterial endotoxin. The IL-6 is expressed at the shoulder of athero- 176
4 Vol 39 Number 4 October - December 2007 The Cut-off Point of Interleukin-6 in Acute Coronary Syndrome CONCLUSION Serum IL-6 level in patients with ACS is higher compared to patients with CHD. Serum IL-6 level with cut-off point > 4.43 pg/ml could differ ACS from CHD with highest sensitivity and speci city (sensitivity %, speci city %, ROC 0.87). Figure 1. ROC serum IL-6 level in acute condition (ACS) compared to non acute condition (CHD) sclerotic plague and is able to increase plague instability through the metalloproteinase matrix expression, the MCP-1 and TNF-α. 19 In this study the serum IL-6 level in ACS is higher compared to CHD. This reveals the role of IL-6 in the pathophysiology of ACS with strong positive correlation with hscrp level (r=0.80, p=0.00) (data not shown). This correlation also shows an increase of acute phase protein through cytokine in ammation pathway. Several studies have found serum IL-6 level to be higher in UAP 9,10,20 and AMI 21,10 compared to CHD patients. Biasucci et al 9 reported that in UAP patients, the elevated serum IL-6 level within 48 hours after hospitalization compared to the level on admission, associated with combined end point death, myocardial infarction, and refractory angina. 9 In the FRISC-II (Fragmin and/or early Revascularization during InStability in Coronary artery disease) study, increased serum IL-6 level (>5 pg/ml) was associated with mortality after 6 and 12 months. 22 The elevated serum IL-6 level was also identified in patient subgroup who obtained the highest bene t of mortality reduction in early invasive strategy. This shows that elevated serum IL-6 level could identify patients with more severe event index, who receive the bene t with more aggressive treatment. In order to predict ACS event, the > 4.43 pg/ml serum IL-6 level cutoff point was obtained, with 80.95% sensitivity and 77.42% speci city. The serum IL-6 level cutoff point was illustrated in the receiver operating characteristic curve as seen in Figure 1. this means that the serum IL-6 level is adequate to predict the possibility of someone to experience acute condition (ACS) when the serum IL-6 level is found to be > 4.43 pg/ml in CHD. REFERENCES 1. Ross R. Atherosclerosis-an in ammatory disease. N Engl J Med. 1999;340: Tracy RP. In ammation markers and coronary heart disease. Curr Opin Lipidol. 1999;10: Koenig W. Atherosclerosis involves more than just lipids: focus on in ammation. Eur Heart J. 1999;1(suppl T):T19-T Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105: Reape TJ, Groot PHE. Chemokines and atherosclerosis. Atherosclerosis. 1999;147: Terkeltaub R, Boisvert WA, Curtiss LK. Chemokines and atherosclerosis. Curr Opin Lipidol. 1998;9: Frostegard J, Ulfgren AK, Nyberg P, et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-in ammatory (Th-1) and macrophage stimulating cytokines. Atherosclerosis. 1999;145: Ikonomidis I, Andreotti F, Economou E, et al. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation.1999;100: Biasucci LM, Liuzzo G, Fantuzzi G, et al. Increasing levels of interleukin (IL)-1Ra and IL-6 during the rst 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation. 1999;99: Neumann FJ, Ott I, Gawaz M, et al. Cardiac release of cytokines and in ammatory responses in acute myocardial infarction. Circulation. 1995;92: Ridker PM, Rifai N, Stampfer MJ, et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation.2000;101: Smith DA, Irving SD, Sheldon J, et al. Serum levels of the anti-in ammatory cytokine interleukin-10 are decreased in patients with unstable angina. Circulation. 2001;104: Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). Circulation 2004;110: Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-st-segment elevation myocardial infarction 2002: Summary article. Circulation. 2002;106: Braunwald E. Unstable angina: a classi cation. Circulation. 1989;80: Campeau L. Grading of angina pectoris (letter). Circulation. 1976;54:
5 Idrus Alwi, et al Acta Med Indones-Indones J Intern Med 17. Alpert JS, Thugesen K, Antman E, et al. Myocardial infarction rede ned-a consensus document of the joint European Society of Cardiology/American College of Cardiology committee for the rede nition of myocardial infarction. J Am Coll Cardiol. 2000;36: Woods A, Brull DJ, Humphries SE, et al. Genetics of in ammations and risk of coronary artery disease: the central role of interleukin-6. Eur Heart J. 2000;21: Schieffer B, Schieffer E, Hil ker-kleiner D, et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques. Circulation. 2000;101: Biasucci LM, Vitelli A, Liuzzo G, et al. Elevated levels of interleukin-6 in unstable angina. Circulation. 1996;94: Liuzzo G, Biasucci LM, Gallimore JR, et al. Enhanced in ammatory response in patients with preinfarction unstable angina. J Am Coll Cardiol. 1999;34: Lindmark E, Diderholm E, Wallentin L, et al. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease. JAMA. 2001;286:
Interleukin-10 serum level in acute coronary syndrome patients
167 Interleukin-10 serum level in acute coronary syndrome patients Idrus Alwi, 1 Teguh Santoso, 1 Slamet Suyono, 2 Bambang Sutrisna, 3 Siti B. Kresno, 4 1 Cardiology Division, Department of Internal Medicine,
More informationA. BISOC 1,2 A.M. PASCU 1 M. RĂDOI 1,2
Bulletin of the Transilvania University of Braşov Series VI: Medical Sciences Vol. 5 (54) No. 2-2012 THE ctntg4 PLASMA LEVELS IN RELATION TO ELECTROCARDIOGRAPHIC AND ECHOCARDIOGRAPHIC ABNORMALITIES IN
More informationIschemic heart disease is the leading cause of
The impact of C-Reactive Protein: A Look at the Most Recent Studies and Trials By Davinder S. Jassal, MD, FRCPC; and Blair O Neill, MD, FRCPC, FACC Ischemic heart disease is the world s leading killer,
More informationATHEROSCLEROSIS IS CHARACterized
ORIGINAL CONTRIBUTION Relationship Between Interleukin 6 and Mortality in Patients With Unstable Coronary Artery Disease Effects of an Early Invasive or Noninvasive Eva Lindmark, MMed Erik Diderholm, MD
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationAutonomic nervous system, inflammation and preclinical carotid atherosclerosis in depressed subjects with coronary risk factors
Autonomic nervous system, inflammation and preclinical carotid atherosclerosis in depressed subjects with coronary risk factors Carmine Pizzi 1 ; Lamberto Manzoli 2, Stefano Mancini 3 ; Gigliola Bedetti
More informationPrognostic Value of C-Reactive Protein and Troponin T Level in Patients With Unstable Angina Pectoris C T KASANUKI, MD, FJCC
C T Prognostic Value of C-Reactive Protein and Troponin T Level in Patients With Unstable Angina Pectoris Hiroyuki Yukio Hiroshi TANAKA, MD TSURUMI, MD KASANUKI, MD, FJCC Abstract Objectives. The prognosis
More informationAPPENDIX F: CASE REPORT FORM
APPENDIX F: CASE REPORT FORM Instruction: Complete this form to notify all ACS admissions at your centre to National Cardiovascular Disease Registry. Where check boxes are provided, check ( ) one or more
More informationSerial changes in plasma levels of cytokines in patients with coronary artery disease
ORIGINAL RESEARCH Serial changes in plasma levels of cytokines in patients with coronary artery disease Roberto H Heinisch 1 Carlos R Zanetti 1 Fabiano Comin 1 Juliano L Fernandes 2 José A Ramires 2 Carlos
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationMeasuring Natriuretic Peptides in Acute Coronary Syndromes
Measuring Natriuretic Peptides in Acute Coronary Syndromes Peter A. McCullough, MD, MPH, FACC, FACP, FAHA, FCCP Consultant Cardiologist Chief Academic and Scientific Officer St. John Providence Health
More informationROLE OF INFLAMMATION IN HYPERTENSION. Dr Barasa FA Physician Cardiologist Eldoret
ROLE OF INFLAMMATION IN HYPERTENSION Dr Barasa FA Physician Cardiologist Eldoret Outline Inflammation in CVDs the evidence Basic Science in Cardiovascular inflammation: The Main players Inflammation as
More informationA: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups
A: Epidemiology update Evidence that LDL-C and CRP identify different high-risk groups Women (n = 27,939; mean age 54.7 years) who were free of symptomatic cardiovascular (CV) disease at baseline were
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationAcute Coronary Syndrome
ACUTE CORONOARY SYNDROME, ANGINA & ACUTE MYOCARDIAL INFARCTION Administrative Consultant Service 3/17 Acute Coronary Syndrome Acute Coronary Syndrome has evolved as a useful operational term to refer to
More informationI t is becoming increasingly clear that inflammation plays a
25 CARDIOVASCULAR MEDICINE Raised concentrations of macrophage colony stimulating factor in severe unstable angina beyond the acute phase are strongly predictive of long term outcome L S Rallidis, M G
More informationJournal of the American College of Cardiology Vol. 36, No. 1, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 36, No. 1, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)00680-X Lack
More informationKnow Your Number Aggregate Report Single Analysis Compared to National Averages
Know Your Number Aggregate Report Single Analysis Compared to National s Client: Study Population: 2242 Population: 3,000 Date Range: 04/20/07-08/08/07 Version of Report: V6.2 Page 2 Study Population Demographics
More informationComparison of Original and Generic Atorvastatin for the Treatment of Moderate Dyslipidemic Patients
Comparison of Original and Generic Atorvastatin for the Treatment of Moderate Dyslipidemic Patients Cardiology Department, Bangkok Metropolitan Medical College and Vajira Hospital, Bangkok, Thailand Abstract
More informationLife Science Journal 2016;13(5) Acute Coronary Syndrome Process In Geriatric Population: One Year Follow-Up Study
Acute Coronary Syndrome Process In Geriatric Population: One Year Follow-Up Study Samim Emet, MD 1, Fatih Akdogan 2, Yucel Arman 2, Murat Kose, MD 3, Basak Saracoglu, MD 4, Tufan Tukek, MD 3 1 Istanbul
More informationPATIENTS AND METHODS:
BACKGROUND: Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease characterized by erosive synovitis that involves peripheral joints and implicates an important influence in the quality
More informationCorrelation of novel cardiac marker
Correlation of novel cardiac marker and mortality in EGAT population. Soluble ST2 hscrp Poh Chanyavanich, MD SukitYamwong, MD Piyamitr Sritara, MD Ramathibodi hospital Background hscrp - the most widely
More informationChest pain affects 20% to 40% of the general population during their lifetime.
Chest pain affects 20% to 40% of the general population during their lifetime. More than 5% of visits in the emergency department, and up to 40% of admissions are because of chest pain. Chest pain is a
More informationAcute coronary syndrome. Dr LM Murray Chemical Pathology Block SA
Acute coronary syndrome Dr LM Murray Chemical Pathology Block SA13-2014 Acute myocardial infarction (MI) MI is still the leading cause of death in many countries It is characterized by severe chest pain,
More informationUPDATE ON THE MANAGEMENTACUTE CORONARY SYNDROME. DR JULES KABAHIZI, Psc (Rwa) Lt Col CHIEF CONSULTANT RMH/KFH 28 JUNE18
UPDATE ON THE MANAGEMENTACUTE CORONARY SYNDROME DR JULES KABAHIZI, Psc (Rwa) Lt Col CHIEF CONSULTANT RMH/KFH 28 JUNE18 INTRODUCTION The clinical entities that comprise acute coronary syndromes (ACS)-ST-segment
More informationC- REACTIVE PROTEIN IN PATIENTS WITH NSTEMI ACUTE CORONARY SYNDROME
C- REACTIVE PROTEIN IN PATIENTS WITH NSTEMI ACUTE CORONARY SYNDROME Dubey RK *, Dhakal N **, Das BKL **, Pandey NK ***, Baral N **, Lamsal M ** * Department of Biochemistry, Universal College of Medical
More informationThe impact of hs C-reactive protein and other inflammatory biomarkers on long-term cardiovascular mortality in patients with acute coronary syndromes
Atherosclerosis 194 (2007) 397 402 The impact of hs C-reactive protein and other inflammatory biomarkers on long-term cardiovascular mortality in patients with acute coronary syndromes Michael N. Zairis,
More informationRisk Stratification of ACS Patients. Frans Van de Werf, MD, PhD University of Leuven, Belgium
Risk Stratification of ACS Patients Frans Van de Werf, MD, PhD University of Leuven, Belgium Which type of ACS patients are we talking about to day? 4/14/2011 STEMI and NSTEMI in the NRMI registry from
More informationStatin pretreatment and presentation patterns in patients with acute coronary syndromes
Brief Report Page 1 of 5 Statin pretreatment and presentation patterns in patients with acute coronary syndromes Marcelo Trivi, Ruth Henquin, Juan Costabel, Diego Conde Cardiovascular Institute of Buenos
More informationCardiovascular Disorders Lecture 3 Coronar Artery Diseases
Cardiovascular Disorders Lecture 3 Coronar Artery Diseases By Prof. El Sayed Abdel Fattah Eid Lecturer of Internal Medicine Delta University Coronary Heart Diseases It is the leading cause of death in
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationRikshospitalet, University of Oslo
Rikshospitalet, University of Oslo Preventing heart failure by preventing coronary artery disease progression European Society of Cardiology Dyslipidemia 29.08.2010 Objectives The trends in cardiovascular
More informationAcute Coronary Syndrome in Phrae Hospital
Acute Coronary Syndrome in Phrae Hospital Cardiovascular Unit, Department of Medicine, Phrae hospital, Phrae Thailand. Objective: To study the epidemiology, management and outcome of patients with acute
More informationThe 10 th International & 15 th National Congress on Quality Improvement in Clinical Laboratories
The 10 th International & 15 th National Congress on Quality Improvement in Clinical Laboratories Cardiac biomarkers in atherosclerosis Najma Asadi MD-APCP Ross and Colleagues in 1973: Response to Injury
More informationÄr dagens troponinmetoder tillräckligt känsliga?
Är dagens troponinmetoder tillräckligt känsliga? Per Venge, MD PhD Professor Department of Medical Sciences Uppsala University and Department of Clinical Chemistry and Pharmacology University Hospital
More informationAcute Coronary Syndrome. Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine
Acute Coronary Syndrome Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine Topics Timing is everything So many drugs to choose from What s a MINOCA? 2 Acute
More informationThe New England Journal of Medicine C-REACTIVE PROTEIN AND OTHER MARKERS OF INFLAMMATION IN THE PREDICTION OF CARDIOVASCULAR DISEASE IN WOMEN
C-REACTIVE PROTEIN AND OTHER MARKERS OF INFLAMMATION IN THE PREDICTION OF CARDIOVASCULAR DISEASE IN WOMEN PAUL M. RIDKER, M.D., CHARLES H. HENNEKENS, M.D., JULIE E. BURING, SC.D., AND NADER RIFAI, PH.D.
More informationA Comparative Evaluation of C-Reactive Protein as a Short-Term Prognostic Marker in Severe Unstable Angina A Preliminary Study
Original Article A Comparative Evaluation of C-Reactive Protein as a Short-Term Prognostic Marker in Severe Unstable Angina A Preliminary Study S Bhagat*, M Gaiha*, VK Sharma**, S Anuradha* Abstract Objective
More informationNovel Risk Markers in ACS (Hyperglycemia, Anemia, GFR)
Novel Risk Markers in ACS (Hyperglycemia, Anemia, GFR) Shaul Atar, MD Department of Cardiology Faculty of Medicine of the Galilee Western Galilee Medical Center, Nahariya, Israel TIMI Risk Score Age 65
More informationThe updated guidelines from the National
BEYOND NCEP ATP III: LESSONS LEARNED AND FUTURE DIRECTIONS * Benjamin J. Ansell, MD, FACP ABSTRACT The National Cholesterol Education Program (NCEP) Third Adult Treatment Panel (ATP III) guidelines provide
More informationCase Study: Chris Arden. Peripheral Arterial Disease
Case Study: Chris Arden Peripheral Arterial Disease Patient Presentation Diane is a 65-year-old retired school teacher She complains of left calf pain when walking 50 metres; the pain goes away after she
More informationJournal of the American College of Cardiology Vol. 40, No. 10, by the American College of Cardiology Foundation ISSN /02/$22.
Journal of the American College of Cardiology Vol. 40, No. 10, 2002 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00 Published by Elsevier Science Inc. PII S0735-1097(02)02484-1
More informationDivision of Cardiovascular Medicine, Jichi Medical University Saitama Medical Center, Japan
Association between continuously elevated C-reactive protein and restenosis after percutaneous coronary intervention using drug-eluting stent in angina patients Division of Cardiovascular Medicine, Jichi
More informationFatality of Future Coronary Events Is Related to Inflammation-Sensitive Plasma Proteins
Fatality of Future Coronary Events Is Related to Inflammation-Sensitive Plasma Proteins A Population-Based Prospective Cohort Study Gunnar Engström, MD; Bo Hedblad, MD; Lars Stavenow, MD; Patrik Tydén,
More informationGuidelines on cardiovascular risk assessment and management
European Heart Journal Supplements (2005) 7 (Supplement L), L5 L10 doi:10.1093/eurheartj/sui079 Guidelines on cardiovascular risk assessment and management David A. Wood 1,2 * 1 Cardiovascular Medicine
More information12/18/2009 Resting and Maxi Resting and Max mal Coronary Blood Flow 2
Coronary Artery Pathophysiology ACS / AMI LeRoy E. Rabbani, MD Director, Cardiac Inpatient Services Director, Cardiac Intensive Care Unit Professor of Clinical Medicine Major Determinants of Myocardial
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More informationThe PAIN Pathway for the Management of Acute Coronary Syndrome
2 The PAIN Pathway for the Management of Acute Coronary Syndrome Eyal Herzog, Emad Aziz, and Mun K. Hong Acute coronary syndrome (ACS) subsumes a spectrum of clinical entities, ranging from unstable angina
More informationTitle for Paragraph Format Slide
Title for Paragraph Format Slide Presentation Title: Month Date, Year Atherosclerosis A Spectrum of Disease: February 12, 2015 Richard Cameron Padgett, MD Executive Medical Director, OHVI Pt RB Age 38
More informationDoes high-sensitivity C-reactive protein add prognostic value to the TIMI-Risk Score in individuals with non-st elevation acute coronary syndromes?
Clinica Chimica Acta 375 (2007) 124 128 www.elsevier.com/locate/clinchim Does high-sensitivity C-reactive protein add prognostic value to the TIMI-Risk Score in individuals with non-st elevation acute
More informationPharmacologyonline 2: (2010) Newsletter Kakadiya and Shah
ROLE OF CREATINE KINASE MB AND LACTATE DEHYDROGENASE IN CARDIAC FUNCTION A REVIEW Jagdish Kakadiya*, Nehal Shah Department of Pharmacology, Dharmaj Degree Pharmacy College, Petlad- Khambhat Road, Dharmaj,
More informationBelinda Green, Cardiologist, SDHB, 2016
Acute Coronary syndromes All STEMI ALL Non STEMI Unstable angina Belinda Green, Cardiologist, SDHB, 2016 Thrombus in proximal LAD Underlying pathophysiology Be very afraid for your patient Wellens
More informationCLINICAL OUTCOME Vs SURROGATE MARKER
CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical
More informationGALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS
GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS Table of Contents List of authors pag 2 Supplemental figure I pag 3 Supplemental figure II pag 4 Supplemental
More informationCardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003
Authorized By: Medical Management Guideline Committee Approval Date: 12/13/01 Revision Date: 12/11/03 Beta-Blockers Nitrates Calcium Channel Blockers MEDICATIONS Indicated in post-mi, unstable angina,
More informationA study on clinical profile of acute coronary syndrome in type 2 diabetes mellitus patients with relevance to HbA1c
Original Research Article A study on clinical profile of acute coronary syndrome in type 2 diabetes mellitus patients with relevance to HbA1c K. Babu Raj 1, G. Sivachandran 2* 1 Reader, 2 Final Year Post
More informationSupplementary Online Content
Supplementary Online Content Larsen JR, Vedtofte L, Jakobsen MSL, et al. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia
More informationThe Metabolic Syndrome Update The Metabolic Syndrome: Overview. Global Cardiometabolic Risk
Update 2013 Marc Cornier, M.D. Associate Professor of Medicine Division of Endocrinology, Metabolism & Diabetes Anschutz Health and Wellness Center University of Colorado School of Medicine Denver Health
More informationSupplementary table 1 Demographic and clinical characteristics of participants by paraoxonase-1 (PON-1) gene polymorphisms
Supplementary table 1 Demographic and clinical characteristics of participants by paraoxonase-1 (PON-1) gene polymorphisms QQ QR/RR n = 36 n = 80 Men (%) 20 (55) 54 (67) 0.216 Age (years) 57 ± 10 56 ±
More informationCase Study 50 YEAR OLD MALE WITH UNSTABLE ANGINA
Case Study 50 YEAR OLD MALE WITH UNSTABLE ANGINA Case History A 50-year-old man with type 1 diabetes mellitus and hypertension presents after experiencing 1 hour of midsternal chest pain that began after
More informationSMARTool clinical and biohumoral results. Chiara Caselli IFC-CNR
SMARTool clinical and biohumoral results Chiara Caselli IFC-CNR SMARTool Flow chart EVINCI and ARTreat Populations SMARTool: WP1 and WP2 WP1 Objective: To collect retrospective EVINCI clinical and imaging
More informationCLINICIAN INTERVIEW RECOGNIZING ACS AND STRATIFYING RISK IN PRIMARY CARE. An interview with A. Michael Lincoff, MD, and Eric R. Bates, MD, FACC, FAHA
RECOGNIZING ACS AND STRATIFYING RISK IN PRIMARY CARE An interview with A. Michael Lincoff, MD, and Eric R. Bates, MD, FACC, FAHA Dr Lincoff is an interventional cardiologist and the Vice Chairman for Research
More informationComparison of Mean Platelet Volume in Acute Myocardial Infarction vs. Normal Coronary Angiography
Global Journal of Health Science; Vol. 8, No. 11; 2016 ISSN 1916-9736 E-ISSN 1916-9744 Published by Canadian Center of Science and Education Comparison of Mean Platelet Volume in Acute Myocardial Infarction
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationMany cardiovascular events occur in persons without
Inflammatory Markers and Onset of Cardiovascular Events Results From the Health ABC Study Matteo Cesari, MD; Brenda W.J.H. Penninx, PhD; Anne B. Newman, MD, MPH; Stephen B. Kritchevsky, PhD; Barbara J.
More informationLife Science Journal 2018;15(12)
Multicenter observational study of risk factors profile in a sample of Egyptian Patients with Acute Coronary Syndrome (part of Egyptian Cardiovascular Risk Factors Project) Prof. Dr. Ahmed Ashraf Reda,
More informationIn an attempt to improve global cardiovascular risk
MINI-REVIEW: EXPERT OPINIONS Clinical Application of C-Reactive Protein for Cardiovascular Disease Detection and Prevention Paul M Ridker, MD In an attempt to improve global cardiovascular risk prediction,
More informationSpotty Calcification as a Marker of Accelerated Progression of Coronary Atherosclerosis : Insights from Serial Intravascular Ultrasound
Spotty Calcification as a Marker of Accelerated Progression of Coronary Atherosclerosis : Insights from Serial Intravascular Ultrasound Department of Cardiovascular Medicine Heart and Vascular Institute
More informationStatins. ( Acute coronary syndrome ) Statins. ( Evidence-based medicine ) ( ST ST ) Statins. statins. stains. statins
2006 17 45-51 Statins Statins ST ) ( ST stains Statins ( Acute coronary syndrome ) ( Evidence-based medicine ) 2 100 1 20% 5% Glasgow MONICA 17 20-30% 30-50% 30-40% 35% ( revascularization ) (WOSCOS 4-S
More informationMultiple Inflammatory Prognostic Factors in Acute Coronary Syndromes: A Prospective Inception Cohort Study
ORIGINAL REPORT Multiple Inflammatory Prognostic Factors in Acute Coronary Syndromes: A Prospective Inception Cohort Study Zinat Nadia Hatmi *1, Ali Kazemi Saeid 2, Mohammad Ali Broumand 3, Shabnam Najar
More informationpulmonary artery vasoreactivity in patients with idiopathic pulmonary arterial hypertension
Supplementary material Jonas K, Magoń W, Waligóra M, et al. High density lipoprotein cholesterol levels and pulmonary artery vasoreactivity in patients with idiopathic pulmonary arterial hypertension Pol
More informationSupplementary Online Content. Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and
1 Supplementary Online Content 2 3 4 5 6 Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and cardiometabolic risk factor management on sympton burden and severity in patients with atrial
More informationFastTest. You ve read the book now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. The answers will refer you back to
More informationEffects of Statins on Endothelial Function in Patients with Coronary Artery Disease
Effects of Statins on Endothelial Function in Patients with Coronary Artery Disease Iana I. Simova, MD; Stefan V. Denchev, PhD; Simeon I. Dimitrov, PhD Clinic of Cardiology, University Hospital Alexandrovska,
More informationIschemic Heart Disease
Ischemic Heart Disease Dr Rodney Itaki Lecturer Division of Pathology University of Papua New Guinea School of Medicine & Health Sciences Division of Pathology General Consideration Results from partial
More informationThe Framingham Coronary Heart Disease Risk Score
Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score Michelle A. Albert, MD, MPH; Robert J. Glynn, PhD; Paul M Ridker, MD, MPH Background Although
More informationThe TNT Trial Is It Time to Shift Our Goals in Clinical
The TNT Trial Is It Time to Shift Our Goals in Clinical Angioplasty Summit Luncheon Symposium Korea Assoc Prof David Colquhoun 29 April 2005 University of Queensland, Wesley Hospital, Brisbane, Australia
More informationSupplementary Online Content
Supplementary Online Content Kavousi M, Leening MJG, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines
More informationDIFFERENTIATING THE PATIENT WITH UNDIFFERENTIATED CHEST PAIN
DIFFERENTIATING THE PATIENT WITH UNDIFFERENTIATED CHEST PAIN Objectives Gain competence in evaluating chest pain Recognize features of moderate risk unstable angina Review initial management of UA and
More informationAssessment of vitamin D levels in patients with acute coronary syndrome
ORIGINAL ARTICLE East J Med 21(4): 178-182, 2016 Assessment of vitamin D levels in patients with acute coronary syndrome Hakki Simsek and Naci Babat * Yuzuncu Yil University, Faculty of Medicine, Cardiology
More informationThe Metabolic Syndrome Update The Metabolic Syndrome Update. Global Cardiometabolic Risk
The Metabolic Syndrome Update 2018 Marc Cornier, M.D. Professor of Medicine Division of Endocrinology, Metabolism & Diabetes Anschutz Health and Wellness Center University of Colorado School of Medicine
More informationCho et al., 2009 Journal of Cardiology (2009), 54:
Endothelial Dysfunction, Increased Carotid Artery Intima-media Thickness and Pulse Wave Velocity, and Increased Level of Inflammatory Markers are Associated with Variant Angina Cho et al., 2009 Journal
More informationPrognostic Significance of High Sensitivity C-Reactive Protein before and after Percutaneous Coronary Intervention in Patients with Angina Pectoris
Med. J. Cairo Univ., Vol. 80, No. 2, June: 267-272, 2012 www.medicaljournalofcairouniversity.com Prognostic Significance of High Sensitivity C-Reactive Protein before and after Percutaneous Coronary Intervention
More informationTIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS
European Heart Journal (2005) 26, 865 872 doi:10.1093/eurheartj/ehi187 Clinical research TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS
More informationOptimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden
Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD
More informationAn update on the management of UA / NSTEMI. Michael H. Crawford, MD
An update on the management of UA / NSTEMI Michael H. Crawford, MD New ACC/AHA Guidelines 2007 What s s new in the last 5 years CT imaging advances Ascendancy of troponin and BNP Clarification of ACEI/ARB
More informationCVD Prevention, Who to Consider
Continuing Professional Development 3rd annual McGill CME Cruise September 20 27, 2015 CVD Prevention, Who to Consider Dr. Guy Tremblay Excellence in Health Care and Lifelong Learning Global CV risk assessment..
More informationRelationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome
Relationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome Helder Dores, Luís Bronze Carvalho, Ingrid Rosário, Sílvio Leal, Maria João
More informationTotal risk management of Cardiovascular diseases Nobuhiro Yamada
Nobuhiro Yamada The worldwide burden of cardiovascular diseases (WHO) To prevent cardiovascular diseases Beyond LDL Multiple risk factors With common molecular basis The Current Burden of CVD CVD is responsible
More informationOf the 1.5 million heart attacks
CARDIOLOGY PATIENT PAGE CARDIOLOGY PATIENT PAGE C-Reactive Protein A Simple Test to Help Predict Risk of Heart Attack and Stroke Paul M Ridker, MD, MPH Of the 1.5 million heart attacks and 600 000 strokes
More informationResearch Article Comparison of Different Anthropometric Measurements and Inflammatory Biomarkers
International Inflammation Volume 2012, Article ID 124693, 5 pages doi:10.1155/2012/124693 Research Article Comparison of Different Anthropometric Measurements and Inflammatory Biomarkers Yaron Arbel,
More informationPredictor Value Cytokines for Recurrence of. Arrhythmia in Patients with Coronary Heart. Disease Combined Hypertension and Persistent
Biological Markers and Guided Therapy, Vol. 1, 2014, no. 2, 109-114 HIKARI Ltd, www.m-hikari.com http://dx.doi.org/10.12988/bmgt.2014.41012 Predictor Value Cytokines for Recurrence of Arrhythmia in Patients
More informationAcute coronary syndrome (ACS) is a potentially
DIAGNOSING ACUTE CORONARY SYNDROME AND DETERMINING PATIENT RISK Edith A. Nutescu, PharmD* ABSTRACT Acute coronary syndrome is a form of coronary artery disease and has a broad range of clinical presentations.
More informationBiomarkers in Acute Cardiac Disease Samir Arnaout, M.D.FESC Associate Professor of Medicine Internal Medicine i & Cardiology American University of Beirut Time course of the appearance of various markers
More informationCRP and fibrinogen imply clinical outcome of patients with type-2 diabetes. and coronary artery disease
CRP and fibrinogen imply clinical outcome of patients with type-2 diabetes and coronary artery disease Marijan Bosevski 1, *, Golubinka Bosevska 1, Lily Stojanovska 2, Vasso Apostolopoulos 2, * 1 University
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More informationEvaluation of hs-crp levels in acute coronary syndromes
Original Research Article Evaluation of hs-crp levels in acute coronary syndromes R. S. Pushpa Kumari 1*, Priya John 2, V. A. Vipula 3 1 Professor, Department of General Medicine, MNR Medical College and
More information